At the recent CPRIT Oversight Committee meeting, six innovative Texas-based companies presented groundbreaking cancer therapies that could reshape treatment options for patients.

Leading the charge is Crossbridge Bio, a Houston firm focused on advanced antibody drug conjugates (ADCs) targeting various cancers, including breast and lung. Their proprietary technology, developed in collaboration with UT Health Houston, aims to enhance drug stability and combat cancer cell resistance. Their lead asset, CBB120, will be compared to Trodelvi, an existing TROP2-targeting drug, in hopes of improving patient outcomes.

Next up is Akaa Biologics from Frisco, which is developing a novel antibody designed to engage immune cells in the tumor microenvironment for advanced non-small cell lung cancer. This innovative approach could significantly impact treatment for patients whose tumors do not respond to standard therapies.

Southern Hills Pharma, also based in Houston, is working on an integrin agonist to improve stem cell transplants for leukemia patients. Their product aims to address the challenges of donor availability and infection risks, particularly among Hispanic, Latino, and Black patients, who represent a significant portion of Texas's population.

Endapta Therapeutics is another Houston company making waves with its development of potent natural killer cells for treating multiple myeloma and non-Hodgkin's lymphoma. Their off-the-shelf cryopreserved product, IDP23, promises fewer side effects and easier administration, potentially offering new hope for patients with limited treatment options.

Bectus Therapeutics is tackling myeloid-dependent resistance to T-cell checkpoint therapy. Their research has identified specific biomarkers for patient selection, allowing for more precise treatment strategies that could enhance survival rates in solid tumor cases.

These companies represent a promising future in cancer treatment, with innovative solutions that could significantly improve patient care and outcomes across Texas and beyond. The committee's support for these initiatives underscores a commitment to advancing cancer research and addressing disparities in treatment access.